AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer's disease.
Shanghai, China. In Curr Neuropharmacol, Feb 2016
Herein, we delineated the catalytic and non-catalytic functions of AChE, and summarized the works of our group and others in research and development of novel AChEI-based multi-target-directed ligands (MTDLs), such as dual binding site AChEIs and multi-target AChEIs inhibiting Aβ aggregation, regulating Aβ procession, antagonizing PAF receptor, scavenging oxygen radical, chelating metal ions, inhibiting MAO-B, blocking NMDA receptor and others.
Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold.
Cagliari, Italy. In Eur J Med Chem, Jan 2016
UNASSIGNED: With the aim to identify new, potent and selective monoamine oxidase B (MAO-B) inhibitors, molecular interaction field analysis has been applied to a MAO-B complex with 3-acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazole chemical structure, known as a privileged scaffold for this target.
Parkinson's disease: fewer treatment withdrawals with levodopa.
In Prescrire Int, Dec 2015
In mid-2015, interim results of a randomised trial conducted in the routine care setting, involving 1620 patients with newly diagnosed Parkinson's disease, showed that levodopa was slightly more effective in terms of mobility than dopamine agonists or MAO-B inhibitors, after a median follow-up of 3 years.
Safinamide for symptoms of Parkinson's disease.
Berlin, Germany. In Drugs Today (barc), Nov 2015
Ideal candidates for the balance of these neurotransmitter deficits are compounds like safinamide with broad mechanisms of action such as reversible monoamine oxidase type B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release.
Pharmacological treatment of Parkinson disease: a review.
Hamilton, Canada. In Jama, 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.